Drugs / Pentoxiphylline
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01384578 | Jul 2011 → Nov 2013 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT02458079 | Dec 2014 → Jul 2016 | alcoholic hepatitis | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02231333 Comparator | Jul 2013 → Jul 2015 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentoxiphylline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02231333 ↗ |
| Known as | PTX | “Pentoxiphylline (PTX), an anti-TNF-alpha agent, has been reported to reduce hepatic inflammation and fibrosis.” PMID 33772456 ↗ Mar 20211“pentoxiphylline (PTX)” NCT02231333 ↗ |
| Action | Inhibit | “Pentoxiphylline (PTX), an anti-TNF-alpha agent, has been reported to reduce hepatic inflammation and fibrosis.” PMID 33772456 ↗ Mar 2021 |
| Target | TNF | “Pentoxiphylline (PTX), an anti-TNF-alpha agent” PMID 33772456 ↗ Mar 2021 |